The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Chronic Hepatitis B Oral Drugs Market Research Report 2025
Synopsis
The global Chronic Hepatitis B Oral Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Chronic Hepatitis B Oral Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Chronic Hepatitis B Oral Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Chronic Hepatitis B Oral Drugs include GSK, Bristol Myers Squibb, Gilead Sciences, Novartis, Roche, Merck, Johnson & Johnson, Dawnrays Pharmaceutical and Hansoh Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Chronic Hepatitis B Oral Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Hepatitis B Oral Drugs.
Report Scope
The Chronic Hepatitis B Oral Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Hepatitis B Oral Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Hepatitis B Oral Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Bristol Myers Squibb
Gilead Sciences
Novartis
Roche
Merck
Johnson & Johnson
Dawnrays Pharmaceutical
Hansoh Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
Qilu pharmaceutical
Fujian Cosunter Pharma
Xiamen Amoytop Biotech
YaoPharma
Kelun Pharmaceutical
Segment by Type
Entecavir
Tenofovir
Lamivudine
Adefovir
Telbivudine
Others
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Chronic Hepatitis B Oral Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Chronic Hepatitis B Oral Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Chronic Hepatitis B Oral Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Chronic Hepatitis B Oral Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Chronic Hepatitis B Oral Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Chronic Hepatitis B Oral Drugs include GSK, Bristol Myers Squibb, Gilead Sciences, Novartis, Roche, Merck, Johnson & Johnson, Dawnrays Pharmaceutical and Hansoh Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Chronic Hepatitis B Oral Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Hepatitis B Oral Drugs.
Report Scope
The Chronic Hepatitis B Oral Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Hepatitis B Oral Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Hepatitis B Oral Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Bristol Myers Squibb
Gilead Sciences
Novartis
Roche
Merck
Johnson & Johnson
Dawnrays Pharmaceutical
Hansoh Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
Qilu pharmaceutical
Fujian Cosunter Pharma
Xiamen Amoytop Biotech
YaoPharma
Kelun Pharmaceutical
Segment by Type
Entecavir
Tenofovir
Lamivudine
Adefovir
Telbivudine
Others
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Chronic Hepatitis B Oral Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Chronic Hepatitis B Oral Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Chronic Hepatitis B Oral Drugs Market Overview
1.1 Product Overview and Scope of Chronic Hepatitis B Oral Drugs
1.2 Chronic Hepatitis B Oral Drugs Segment by Type
1.2.1 Global Chronic Hepatitis B Oral Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Entecavir
1.2.3 Tenofovir
1.2.4 Lamivudine
1.2.5 Adefovir
1.2.6 Telbivudine
1.2.7 Others
1.3 Chronic Hepatitis B Oral Drugs Segment by Application
1.3.1 Global Chronic Hepatitis B Oral Drugs Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Chronic Hepatitis B Oral Drugs Market Size Estimates and Forecasts
1.4.1 Global Chronic Hepatitis B Oral Drugs Revenue 2019-2030
1.4.2 Global Chronic Hepatitis B Oral Drugs Sales 2019-2030
1.4.3 Global Chronic Hepatitis B Oral Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Chronic Hepatitis B Oral Drugs Market Competition by Manufacturers
2.1 Global Chronic Hepatitis B Oral Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Chronic Hepatitis B Oral Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Chronic Hepatitis B Oral Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Chronic Hepatitis B Oral Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Chronic Hepatitis B Oral Drugs, Product Type & Application
2.7 Chronic Hepatitis B Oral Drugs Market Competitive Situation and Trends
2.7.1 Chronic Hepatitis B Oral Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Chronic Hepatitis B Oral Drugs Players Market Share by Revenue
2.7.3 Global Chronic Hepatitis B Oral Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Chronic Hepatitis B Oral Drugs Retrospective Market Scenario by Region
3.1 Global Chronic Hepatitis B Oral Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Chronic Hepatitis B Oral Drugs Global Chronic Hepatitis B Oral Drugs Sales by Region: 2019-2030
3.2.1 Global Chronic Hepatitis B Oral Drugs Sales by Region: 2019-2024
3.2.2 Global Chronic Hepatitis B Oral Drugs Sales by Region: 2025-2030
3.3 Global Chronic Hepatitis B Oral Drugs Global Chronic Hepatitis B Oral Drugs Revenue by Region: 2019-2030
3.3.1 Global Chronic Hepatitis B Oral Drugs Revenue by Region: 2019-2024
3.3.2 Global Chronic Hepatitis B Oral Drugs Revenue by Region: 2025-2030
3.4 North America Chronic Hepatitis B Oral Drugs Market Facts & Figures by Country
3.4.1 North America Chronic Hepatitis B Oral Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Chronic Hepatitis B Oral Drugs Sales by Country (2019-2030)
3.4.3 North America Chronic Hepatitis B Oral Drugs Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Chronic Hepatitis B Oral Drugs Market Facts & Figures by Country
3.5.1 Europe Chronic Hepatitis B Oral Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Chronic Hepatitis B Oral Drugs Sales by Country (2019-2030)
3.5.3 Europe Chronic Hepatitis B Oral Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Netherlands
3.6 Asia Pacific Chronic Hepatitis B Oral Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Chronic Hepatitis B Oral Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Chronic Hepatitis B Oral Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Chronic Hepatitis B Oral Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Southeast Asia
3.6.9 China Taiwan
3.6.10 Australia
3.7 Latin America Chronic Hepatitis B Oral Drugs Market Facts & Figures by Country
3.7.1 Latin America Chronic Hepatitis B Oral Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Chronic Hepatitis B Oral Drugs Sales by Country (2019-2030)
3.7.3 Latin America Chronic Hepatitis B Oral Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Chronic Hepatitis B Oral Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Chronic Hepatitis B Oral Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Chronic Hepatitis B Oral Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Chronic Hepatitis B Oral Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Chronic Hepatitis B Oral Drugs Sales by Type (2019-2030)
4.1.1 Global Chronic Hepatitis B Oral Drugs Sales by Type (2019-2024)
4.1.2 Global Chronic Hepatitis B Oral Drugs Sales by Type (2025-2030)
4.1.3 Global Chronic Hepatitis B Oral Drugs Sales Market Share by Type (2019-2030)
4.2 Global Chronic Hepatitis B Oral Drugs Revenue by Type (2019-2030)
4.2.1 Global Chronic Hepatitis B Oral Drugs Revenue by Type (2019-2024)
4.2.2 Global Chronic Hepatitis B Oral Drugs Revenue by Type (2025-2030)
4.2.3 Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Chronic Hepatitis B Oral Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Chronic Hepatitis B Oral Drugs Sales by Application (2019-2030)
5.1.1 Global Chronic Hepatitis B Oral Drugs Sales by Application (2019-2024)
5.1.2 Global Chronic Hepatitis B Oral Drugs Sales by Application (2025-2030)
5.1.3 Global Chronic Hepatitis B Oral Drugs Sales Market Share by Application (2019-2030)
5.2 Global Chronic Hepatitis B Oral Drugs Revenue by Application (2019-2030)
5.2.1 Global Chronic Hepatitis B Oral Drugs Revenue by Application (2019-2024)
5.2.2 Global Chronic Hepatitis B Oral Drugs Revenue by Application (2025-2030)
5.2.3 Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Chronic Hepatitis B Oral Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Corporation Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Chronic Hepatitis B Oral Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 GSK Chronic Hepatitis B Oral Drugs Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Bristol Myers Squibb
6.2.1 Bristol Myers Squibb Corporation Information
6.2.2 Bristol Myers Squibb Description and Business Overview
6.2.3 Bristol Myers Squibb Chronic Hepatitis B Oral Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bristol Myers Squibb Chronic Hepatitis B Oral Drugs Product Portfolio
6.2.5 Bristol Myers Squibb Recent Developments/Updates
6.3 Gilead Sciences
6.3.1 Gilead Sciences Corporation Information
6.3.2 Gilead Sciences Description and Business Overview
6.3.3 Gilead Sciences Chronic Hepatitis B Oral Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Gilead Sciences Chronic Hepatitis B Oral Drugs Product Portfolio
6.3.5 Gilead Sciences Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Chronic Hepatitis B Oral Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novartis Chronic Hepatitis B Oral Drugs Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Roche
6.5.1 Roche Corporation Information
6.5.2 Roche Description and Business Overview
6.5.3 Roche Chronic Hepatitis B Oral Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Roche Chronic Hepatitis B Oral Drugs Product Portfolio
6.5.5 Roche Recent Developments/Updates
6.6 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck Chronic Hepatitis B Oral Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Merck Chronic Hepatitis B Oral Drugs Product Portfolio
6.6.5 Merck Recent Developments/Updates
6.7 Johnson & Johnson
6.6.1 Johnson & Johnson Corporation Information
6.6.2 Johnson & Johnson Description and Business Overview
6.6.3 Johnson & Johnson Chronic Hepatitis B Oral Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Johnson & Johnson Chronic Hepatitis B Oral Drugs Product Portfolio
6.7.5 Johnson & Johnson Recent Developments/Updates
6.8 Dawnrays Pharmaceutical
6.8.1 Dawnrays Pharmaceutical Corporation Information
6.8.2 Dawnrays Pharmaceutical Description and Business Overview
6.8.3 Dawnrays Pharmaceutical Chronic Hepatitis B Oral Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Dawnrays Pharmaceutical Chronic Hepatitis B Oral Drugs Product Portfolio
6.8.5 Dawnrays Pharmaceutical Recent Developments/Updates
6.9 Hansoh Pharmaceutical
6.9.1 Hansoh Pharmaceutical Corporation Information
6.9.2 Hansoh Pharmaceutical Description and Business Overview
6.9.3 Hansoh Pharmaceutical Chronic Hepatitis B Oral Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Hansoh Pharmaceutical Chronic Hepatitis B Oral Drugs Product Portfolio
6.9.5 Hansoh Pharmaceutical Recent Developments/Updates
6.10 Chia Tai-Tianqing Pharmaceutical
6.10.1 Chia Tai-Tianqing Pharmaceutical Corporation Information
6.10.2 Chia Tai-Tianqing Pharmaceutical Description and Business Overview
6.10.3 Chia Tai-Tianqing Pharmaceutical Chronic Hepatitis B Oral Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Chia Tai-Tianqing Pharmaceutical Chronic Hepatitis B Oral Drugs Product Portfolio
6.10.5 Chia Tai-Tianqing Pharmaceutical Recent Developments/Updates
6.11 Qilu pharmaceutical
6.11.1 Qilu pharmaceutical Corporation Information
6.11.2 Qilu pharmaceutical Chronic Hepatitis B Oral Drugs Description and Business Overview
6.11.3 Qilu pharmaceutical Chronic Hepatitis B Oral Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Qilu pharmaceutical Chronic Hepatitis B Oral Drugs Product Portfolio
6.11.5 Qilu pharmaceutical Recent Developments/Updates
6.12 Fujian Cosunter Pharma
6.12.1 Fujian Cosunter Pharma Corporation Information
6.12.2 Fujian Cosunter Pharma Chronic Hepatitis B Oral Drugs Description and Business Overview
6.12.3 Fujian Cosunter Pharma Chronic Hepatitis B Oral Drugs Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Fujian Cosunter Pharma Chronic Hepatitis B Oral Drugs Product Portfolio
6.12.5 Fujian Cosunter Pharma Recent Developments/Updates
6.13 Xiamen Amoytop Biotech
6.13.1 Xiamen Amoytop Biotech Corporation Information
6.13.2 Xiamen Amoytop Biotech Chronic Hepatitis B Oral Drugs Description and Business Overview
6.13.3 Xiamen Amoytop Biotech Chronic Hepatitis B Oral Drugs Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Xiamen Amoytop Biotech Chronic Hepatitis B Oral Drugs Product Portfolio
6.13.5 Xiamen Amoytop Biotech Recent Developments/Updates
6.14 YaoPharma
6.14.1 YaoPharma Corporation Information
6.14.2 YaoPharma Chronic Hepatitis B Oral Drugs Description and Business Overview
6.14.3 YaoPharma Chronic Hepatitis B Oral Drugs Sales, Revenue and Gross Margin (2019-2024)
6.14.4 YaoPharma Chronic Hepatitis B Oral Drugs Product Portfolio
6.14.5 YaoPharma Recent Developments/Updates
6.15 Kelun Pharmaceutical
6.15.1 Kelun Pharmaceutical Corporation Information
6.15.2 Kelun Pharmaceutical Chronic Hepatitis B Oral Drugs Description and Business Overview
6.15.3 Kelun Pharmaceutical Chronic Hepatitis B Oral Drugs Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Kelun Pharmaceutical Chronic Hepatitis B Oral Drugs Product Portfolio
6.15.5 Kelun Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Chronic Hepatitis B Oral Drugs Industry Chain Analysis
7.2 Chronic Hepatitis B Oral Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Chronic Hepatitis B Oral Drugs Production Mode & Process
7.4 Chronic Hepatitis B Oral Drugs Sales and Marketing
7.4.1 Chronic Hepatitis B Oral Drugs Sales Channels
7.4.2 Chronic Hepatitis B Oral Drugs Distributors
7.5 Chronic Hepatitis B Oral Drugs Customers
8 Chronic Hepatitis B Oral Drugs Market Dynamics
8.1 Chronic Hepatitis B Oral Drugs Industry Trends
8.2 Chronic Hepatitis B Oral Drugs Market Drivers
8.3 Chronic Hepatitis B Oral Drugs Market Challenges
8.4 Chronic Hepatitis B Oral Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Chronic Hepatitis B Oral Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Chronic Hepatitis B Oral Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Chronic Hepatitis B Oral Drugs Market Competitive Situation by Manufacturers in 2023
Table 4. Global Chronic Hepatitis B Oral Drugs Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Chronic Hepatitis B Oral Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Chronic Hepatitis B Oral Drugs Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Chronic Hepatitis B Oral Drugs Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Chronic Hepatitis B Oral Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Chronic Hepatitis B Oral Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Chronic Hepatitis B Oral Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Chronic Hepatitis B Oral Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Chronic Hepatitis B Oral Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Hepatitis B Oral Drugs as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Chronic Hepatitis B Oral Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Chronic Hepatitis B Oral Drugs Sales by Region (2019-2024) & (K Units)
Table 18. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Region (2019-2024)
Table 19. Global Chronic Hepatitis B Oral Drugs Sales by Region (2025-2030) & (K Units)
Table 20. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Region (2025-2030)
Table 21. Global Chronic Hepatitis B Oral Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Region (2019-2024)
Table 23. Global Chronic Hepatitis B Oral Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Region (2025-2030)
Table 25. North America Chronic Hepatitis B Oral Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Chronic Hepatitis B Oral Drugs Sales by Country (2019-2024) & (K Units)
Table 27. North America Chronic Hepatitis B Oral Drugs Sales by Country (2025-2030) & (K Units)
Table 28. North America Chronic Hepatitis B Oral Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Chronic Hepatitis B Oral Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Chronic Hepatitis B Oral Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Chronic Hepatitis B Oral Drugs Sales by Country (2019-2024) & (K Units)
Table 32. Europe Chronic Hepatitis B Oral Drugs Sales by Country (2025-2030) & (K Units)
Table 33. Europe Chronic Hepatitis B Oral Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Chronic Hepatitis B Oral Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Chronic Hepatitis B Oral Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Chronic Hepatitis B Oral Drugs Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Chronic Hepatitis B Oral Drugs Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Chronic Hepatitis B Oral Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Chronic Hepatitis B Oral Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Chronic Hepatitis B Oral Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Chronic Hepatitis B Oral Drugs Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Chronic Hepatitis B Oral Drugs Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Chronic Hepatitis B Oral Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Chronic Hepatitis B Oral Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Chronic Hepatitis B Oral Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Chronic Hepatitis B Oral Drugs Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Chronic Hepatitis B Oral Drugs Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Chronic Hepatitis B Oral Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Chronic Hepatitis B Oral Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Chronic Hepatitis B Oral Drugs Sales (K Units) by Type (2019-2024)
Table 51. Global Chronic Hepatitis B Oral Drugs Sales (K Units) by Type (2025-2030)
Table 52. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Type (2019-2024)
Table 53. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Type (2025-2030)
Table 54. Global Chronic Hepatitis B Oral Drugs Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Chronic Hepatitis B Oral Drugs Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Type (2019-2024)
Table 57. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Type (2025-2030)
Table 58. Global Chronic Hepatitis B Oral Drugs Price (US$/Unit) by Type (2019-2024)
Table 59. Global Chronic Hepatitis B Oral Drugs Price (US$/Unit) by Type (2025-2030)
Table 60. Global Chronic Hepatitis B Oral Drugs Sales (K Units) by Application (2019-2024)
Table 61. Global Chronic Hepatitis B Oral Drugs Sales (K Units) by Application (2025-2030)
Table 62. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Application (2019-2024)
Table 63. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Application (2025-2030)
Table 64. Global Chronic Hepatitis B Oral Drugs Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Chronic Hepatitis B Oral Drugs Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Application (2019-2024)
Table 67. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Application (2025-2030)
Table 68. Global Chronic Hepatitis B Oral Drugs Price (US$/Unit) by Application (2019-2024)
Table 69. Global Chronic Hepatitis B Oral Drugs Price (US$/Unit) by Application (2025-2030)
Table 70. GSK Corporation Information
Table 71. GSK Description and Business Overview
Table 72. GSK Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. GSK Chronic Hepatitis B Oral Drugs Product
Table 74. GSK Recent Developments/Updates
Table 75. Bristol Myers Squibb Corporation Information
Table 76. Bristol Myers Squibb Description and Business Overview
Table 77. Bristol Myers Squibb Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Bristol Myers Squibb Chronic Hepatitis B Oral Drugs Product
Table 79. Bristol Myers Squibb Recent Developments/Updates
Table 80. Gilead Sciences Corporation Information
Table 81. Gilead Sciences Description and Business Overview
Table 82. Gilead Sciences Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Gilead Sciences Chronic Hepatitis B Oral Drugs Product
Table 84. Gilead Sciences Recent Developments/Updates
Table 85. Novartis Corporation Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Novartis Chronic Hepatitis B Oral Drugs Product
Table 89. Novartis Recent Developments/Updates
Table 90. Roche Corporation Information
Table 91. Roche Description and Business Overview
Table 92. Roche Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Roche Chronic Hepatitis B Oral Drugs Product
Table 94. Roche Recent Developments/Updates
Table 95. Merck Corporation Information
Table 96. Merck Description and Business Overview
Table 97. Merck Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Merck Chronic Hepatitis B Oral Drugs Product
Table 99. Merck Recent Developments/Updates
Table 100. Johnson & Johnson Corporation Information
Table 101. Johnson & Johnson Description and Business Overview
Table 102. Johnson & Johnson Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Johnson & Johnson Chronic Hepatitis B Oral Drugs Product
Table 104. Johnson & Johnson Recent Developments/Updates
Table 105. Dawnrays Pharmaceutical Corporation Information
Table 106. Dawnrays Pharmaceutical Description and Business Overview
Table 107. Dawnrays Pharmaceutical Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Dawnrays Pharmaceutical Chronic Hepatitis B Oral Drugs Product
Table 109. Dawnrays Pharmaceutical Recent Developments/Updates
Table 110. Hansoh Pharmaceutical Corporation Information
Table 111. Hansoh Pharmaceutical Description and Business Overview
Table 112. Hansoh Pharmaceutical Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Hansoh Pharmaceutical Chronic Hepatitis B Oral Drugs Product
Table 114. Hansoh Pharmaceutical Recent Developments/Updates
Table 115. Chia Tai-Tianqing Pharmaceutical Corporation Information
Table 116. Chia Tai-Tianqing Pharmaceutical Description and Business Overview
Table 117. Chia Tai-Tianqing Pharmaceutical Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Chia Tai-Tianqing Pharmaceutical Chronic Hepatitis B Oral Drugs Product
Table 119. Chia Tai-Tianqing Pharmaceutical Recent Developments/Updates
Table 120. Qilu pharmaceutical Corporation Information
Table 121. Qilu pharmaceutical Description and Business Overview
Table 122. Qilu pharmaceutical Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Qilu pharmaceutical Chronic Hepatitis B Oral Drugs Product
Table 124. Qilu pharmaceutical Recent Developments/Updates
Table 125. Fujian Cosunter Pharma Corporation Information
Table 126. Fujian Cosunter Pharma Description and Business Overview
Table 127. Fujian Cosunter Pharma Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Fujian Cosunter Pharma Chronic Hepatitis B Oral Drugs Product
Table 129. Fujian Cosunter Pharma Recent Developments/Updates
Table 130. Xiamen Amoytop Biotech Corporation Information
Table 131. Xiamen Amoytop Biotech Description and Business Overview
Table 132. Xiamen Amoytop Biotech Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. Xiamen Amoytop Biotech Chronic Hepatitis B Oral Drugs Product
Table 134. Xiamen Amoytop Biotech Recent Developments/Updates
Table 135. YaoPharma Corporation Information
Table 136. YaoPharma Description and Business Overview
Table 137. YaoPharma Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. YaoPharma Chronic Hepatitis B Oral Drugs Product
Table 139. YaoPharma Recent Developments/Updates
Table 140. Kelun Pharmaceutical Corporation Information
Table 141. Kelun Pharmaceutical Description and Business Overview
Table 142. Kelun Pharmaceutical Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. Kelun Pharmaceutical Chronic Hepatitis B Oral Drugs Product
Table 144. Kelun Pharmaceutical Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Chronic Hepatitis B Oral Drugs Distributors List
Table 148. Chronic Hepatitis B Oral Drugs Customers List
Table 149. Chronic Hepatitis B Oral Drugs Market Trends
Table 150. Chronic Hepatitis B Oral Drugs Market Drivers
Table 151. Chronic Hepatitis B Oral Drugs Market Challenges
Table 152. Chronic Hepatitis B Oral Drugs Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Chronic Hepatitis B Oral Drugs
Figure 2. Global Chronic Hepatitis B Oral Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Chronic Hepatitis B Oral Drugs Market Share by Type in 2023 & 2030
Figure 4. Entecavir Product Picture
Figure 5. Tenofovir Product Picture
Figure 6. Lamivudine Product Picture
Figure 7. Adefovir Product Picture
Figure 8. Telbivudine Product Picture
Figure 9. Others Product Picture
Figure 10. Global Chronic Hepatitis B Oral Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 11. Global Chronic Hepatitis B Oral Drugs Market Share by Application in 2023 & 2030
Figure 12. Hospital
Figure 13. Clinic
Figure 14. Others
Figure 15. Global Chronic Hepatitis B Oral Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Chronic Hepatitis B Oral Drugs Market Size (2019-2030) & (US$ Million)
Figure 17. Global Chronic Hepatitis B Oral Drugs Sales (2019-2030) & (K Units)
Figure 18. Global Chronic Hepatitis B Oral Drugs Average Price (US$/Unit) & (2019-2030)
Figure 19. Chronic Hepatitis B Oral Drugs Report Years Considered
Figure 20. Chronic Hepatitis B Oral Drugs Sales Share by Manufacturers in 2023
Figure 21. Global Chronic Hepatitis B Oral Drugs Revenue Share by Manufacturers in 2023
Figure 22. The Global 5 and 10 Largest Chronic Hepatitis B Oral Drugs Players: Market Share by Revenue in 2023
Figure 23. Chronic Hepatitis B Oral Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 24. Global Chronic Hepatitis B Oral Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 25. North America Chronic Hepatitis B Oral Drugs Sales Market Share by Country (2019-2030)
Figure 26. North America Chronic Hepatitis B Oral Drugs Revenue Market Share by Country (2019-2030)
Figure 27. United States Chronic Hepatitis B Oral Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Canada Chronic Hepatitis B Oral Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Europe Chronic Hepatitis B Oral Drugs Sales Market Share by Country (2019-2030)
Figure 30. Europe Chronic Hepatitis B Oral Drugs Revenue Market Share by Country (2019-2030)
Figure 31. Germany Chronic Hepatitis B Oral Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. France Chronic Hepatitis B Oral Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. U.K. Chronic Hepatitis B Oral Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Italy Chronic Hepatitis B Oral Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Netherlands Chronic Hepatitis B Oral Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Asia Pacific Chronic Hepatitis B Oral Drugs Sales Market Share by Region (2019-2030)
Figure 37. Asia Pacific Chronic Hepatitis B Oral Drugs Revenue Market Share by Region (2019-2030)
Figure 38. China Chronic Hepatitis B Oral Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Japan Chronic Hepatitis B Oral Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. South Korea Chronic Hepatitis B Oral Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. India Chronic Hepatitis B Oral Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Southeast Asia Chronic Hepatitis B Oral Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. China Taiwan Chronic Hepatitis B Oral Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Australia Chronic Hepatitis B Oral Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Latin America Chronic Hepatitis B Oral Drugs Sales Market Share by Country (2019-2030)
Figure 46. Latin America Chronic Hepatitis B Oral Drugs Revenue Market Share by Country (2019-2030)
Figure 47. Mexico Chronic Hepatitis B Oral Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Brazil Chronic Hepatitis B Oral Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Argentina Chronic Hepatitis B Oral Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Chronic Hepatitis B Oral Drugs Sales Market Share by Country (2019-2030)
Figure 51. Middle East & Africa Chronic Hepatitis B Oral Drugs Revenue Market Share by Country (2019-2030)
Figure 52. Turkey Chronic Hepatitis B Oral Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Chronic Hepatitis B Oral Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. UAE Chronic Hepatitis B Oral Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Global Sales Market Share of Chronic Hepatitis B Oral Drugs by Type (2019-2030)
Figure 56. Global Revenue Market Share of Chronic Hepatitis B Oral Drugs by Type (2019-2030)
Figure 57. Global Chronic Hepatitis B Oral Drugs Price (US$/Unit) by Type (2019-2030)
Figure 58. Global Sales Market Share of Chronic Hepatitis B Oral Drugs by Application (2019-2030)
Figure 59. Global Revenue Market Share of Chronic Hepatitis B Oral Drugs by Application (2019-2030)
Figure 60. Global Chronic Hepatitis B Oral Drugs Price (US$/Unit) by Application (2019-2030)
Figure 61. Chronic Hepatitis B Oral Drugs Value Chain
Figure 62. Chronic Hepatitis B Oral Drugs Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
